Generex Biotechnology Signs Letters of Intent to E
Post# of 36537
(Total Views: 305)
Posted On: 09/10/2019 8:58:44 AM
Generex Biotechnology Signs Letters of Intent to Establish NuGenerex Health MSO with Arizona Endocrinology Center & Paradise Valley Family Medicine
8:30 AM ET, 09/10/2019 - GlobeNewswire
MIRAMAR, Fla., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) announces that the Company has signed letters of intent with Arizona Endocrinology Center and Paradise Valley Family Medicine to establish NuGenerex Health, LLC, a management services organization (MSO) focused on the delivery and management of healthcare services for patients with chronic, complex medical conditions, particularly diabetes. Together, the two medical practices currently work in concert to provide primary care and specialty endocrinology healthcare services for a patient population of roughly 65,000 patients, 25,000 of whom are insulin-dependent diabetes patients.
Under the terms of the agreements, Generex Biotechnology will establish NuGenerex Health, LLC as a multispecialty health services provider that provides ancillary healthcare services and disease management solutions for patients living with chronic medical conditions. With an initial focus on the management of complex diabetes patients, NuGenerex Health is designed as an MSO partnership with the medical groups to offer ophthalmology, podiatry and ancillary health services that will provide patients with integrated, concierge care to improve outcomes and reduce costs.
NuGenerex Health will employ ophthalmologists, podiatrists and medical staff to provide ancillary health services for chronic care patients in support of the Arizona clinics. By bringing specialty ancillary care directly to the patients who regularly visit the practices, NuGenerex Health provides an integrated, collaborative care model not only to enhance patient wellbeing, but also to comply with CMS guidelines for diabetes and chronic care management that can lead to 5-star ratings and increased reimbursements. The ultimate goal is to build an HMO to service Medicare Advantage plans.
Dr. Anthony Katz, MD, President of Paradise Valley Family Medicine, commented on the opportunity, “The NuGenerex Health model is an exciting opportunity for our practice and our patients who will clearly benefit from this integrated care approach to the management of chronic diseases, especially diabetes. We have a large population of chronic care patients who will now be able to have their eye exams and podiatric assessments, so crucial to diabetes management, conducted on site at our clinics. We are happy to be part of NuGenerex Health and look forward to our future growth.”
Dr. Rohit Dwivedi, MD, Managing Partner of Arizona Endocrinology Center, said, “The NuGenerex Health MSO will provide the ancillary health and management services that our endocrinology practice needs to provide comprehensive chronic care solutions to our patients with diabetes. Through NuGenerex Health, we will offer these integrated, specialty services, including ophthalmology and podiatry exams and follow-on treatments as recommended by CMS guidelines. As always, we are dedicated to the health and wellbeing of our patients, and these new services are designed to improve outcomes and to reduce healthcare costs through best practices.”
Joe Moscato, President & Chief Executive Officer of Generex, said of the deal, “By establishing NuGenerex Health with our partners at Arizona Endocrinology Center and Paradise Valley Family Medicine, we not only launch a great new MSO model for diabetes management that has benefits for physicians and patients alike, but we also build the foundation for an HMO that we will be launching in the coming months. Plus, with this foundation, we are reinvigorating our long-established diabetes franchise. As we announced yesterday, we have signed a binding letter of intent to acquire 51% of ALTuCELL (http://altucell.com) with their microencapsulation technology and cell therapy systems that have the potential to cure Type I Diabetes. We will also be relaunching the Oral-Lyn development program with a reformulated Oral-Lyn II that is designed to require only two sprays of our patented buccal insulin spray for glycemic control. The Oral-Lyn II development program will be significantly accelerated with the opportunity to conduct the clinical trials required by FDA for approval by working with diabetes specialists and a population of approximately 25,000 insulin-dependent diabetes patients who will be part of NuGenerex Health. We will keep our shareholders apprised of our progress as we build our end-to-end model for physicians and patients with our partners in Arizona.”
8:30 AM ET, 09/10/2019 - GlobeNewswire
MIRAMAR, Fla., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) announces that the Company has signed letters of intent with Arizona Endocrinology Center and Paradise Valley Family Medicine to establish NuGenerex Health, LLC, a management services organization (MSO) focused on the delivery and management of healthcare services for patients with chronic, complex medical conditions, particularly diabetes. Together, the two medical practices currently work in concert to provide primary care and specialty endocrinology healthcare services for a patient population of roughly 65,000 patients, 25,000 of whom are insulin-dependent diabetes patients.
Under the terms of the agreements, Generex Biotechnology will establish NuGenerex Health, LLC as a multispecialty health services provider that provides ancillary healthcare services and disease management solutions for patients living with chronic medical conditions. With an initial focus on the management of complex diabetes patients, NuGenerex Health is designed as an MSO partnership with the medical groups to offer ophthalmology, podiatry and ancillary health services that will provide patients with integrated, concierge care to improve outcomes and reduce costs.
NuGenerex Health will employ ophthalmologists, podiatrists and medical staff to provide ancillary health services for chronic care patients in support of the Arizona clinics. By bringing specialty ancillary care directly to the patients who regularly visit the practices, NuGenerex Health provides an integrated, collaborative care model not only to enhance patient wellbeing, but also to comply with CMS guidelines for diabetes and chronic care management that can lead to 5-star ratings and increased reimbursements. The ultimate goal is to build an HMO to service Medicare Advantage plans.
Dr. Anthony Katz, MD, President of Paradise Valley Family Medicine, commented on the opportunity, “The NuGenerex Health model is an exciting opportunity for our practice and our patients who will clearly benefit from this integrated care approach to the management of chronic diseases, especially diabetes. We have a large population of chronic care patients who will now be able to have their eye exams and podiatric assessments, so crucial to diabetes management, conducted on site at our clinics. We are happy to be part of NuGenerex Health and look forward to our future growth.”
Dr. Rohit Dwivedi, MD, Managing Partner of Arizona Endocrinology Center, said, “The NuGenerex Health MSO will provide the ancillary health and management services that our endocrinology practice needs to provide comprehensive chronic care solutions to our patients with diabetes. Through NuGenerex Health, we will offer these integrated, specialty services, including ophthalmology and podiatry exams and follow-on treatments as recommended by CMS guidelines. As always, we are dedicated to the health and wellbeing of our patients, and these new services are designed to improve outcomes and to reduce healthcare costs through best practices.”
Joe Moscato, President & Chief Executive Officer of Generex, said of the deal, “By establishing NuGenerex Health with our partners at Arizona Endocrinology Center and Paradise Valley Family Medicine, we not only launch a great new MSO model for diabetes management that has benefits for physicians and patients alike, but we also build the foundation for an HMO that we will be launching in the coming months. Plus, with this foundation, we are reinvigorating our long-established diabetes franchise. As we announced yesterday, we have signed a binding letter of intent to acquire 51% of ALTuCELL (http://altucell.com) with their microencapsulation technology and cell therapy systems that have the potential to cure Type I Diabetes. We will also be relaunching the Oral-Lyn development program with a reformulated Oral-Lyn II that is designed to require only two sprays of our patented buccal insulin spray for glycemic control. The Oral-Lyn II development program will be significantly accelerated with the opportunity to conduct the clinical trials required by FDA for approval by working with diabetes specialists and a population of approximately 25,000 insulin-dependent diabetes patients who will be part of NuGenerex Health. We will keep our shareholders apprised of our progress as we build our end-to-end model for physicians and patients with our partners in Arizona.”
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼